TABLE OF CONTENTS
Preface
Executive Summary
Introduction
PART ONE -- The Case for Data Access
I.1 Statutory and OMB Framework
I.1.1 FY 1999 Omnibus Appropriations Act
I.1.2 The Paperwork Reduction Act
I.1.3 Key Provisions of Existing OMB Circular A-110
I.1.4 Text of OMB's Proposed Revisions to Circular A-110
I.2 Policy Arguments Favoring Data Access
I.2.1 Background
I.2.2 Principles of Open Government
I.2.3 Benefits to Government Decision Making
I.2.4 Enhancements to the Scientific Enterprise
I.3 Current Agency Policies and Other Data Access Precedents
I.3.1 U.S. Government Executive Branch Policies
I.3.1.a Presidential Executive Order on Children's Health
I.3.1.b Food and Drug Administration
I.3.1.c National Science Foundation
I.3.1.d National Center for Health Statistics
I.3.1.e Public Health Service of HHS
I.3.1.f National Institutes of Health
I.3.1.g National Aeronautics and Space Administration
I.3.1.h National Institute of Justice of the Department of Justice
I.3.2 Professional Organizations and Journals
I.3.2.a National Research Council
I.3.2.b Institute of Medicine
I.3.2.c American Physical Society
I.3.2.d American Sociological Association
I.3.2.e American Society for Microbiology
I.3.2.f American Statistical Association
I.3.2.g International Statistical Institute
I.3.2.h American Chemical Society Journals
I.3.2.i The British Medical Journal
I.3.2.j Cell
I.3.2.k Cancer Research
I.3.2.l Journal of the American Medical Association
I.3.2.m Nature
I.3.2.n Proceedings of the National Academy of Sciences
I.3.2.o Science
I.3.3 Professional Commentary
I.3.4 Academic and Research Institutions
I.3.4.a Duke University
I.3.4.b Massachusetts Institute of Technology
I.3.4.c Mount Sinai School of Medicine
I.3.4.d University of California at San Francisco
I.3.4.e University of Minnesota
I.3.4.f University of New Mexico
I.3.4.g University of Pennsylvania
I.3.5 State Legislation
I.3.5.a California
I.3.5.b Massachusetts
I.3.5.c Michigan
PART TWO -- Addressing Concerns Over Data Access
II.1 Introduction
II.2 FOIA Exemptions Provide Broad Protection Against Harmful Disclosures
II.2.1 Protection of Privacy Rights
II.2.2 Intellectual Property Protection
II.2.2.a Introduction
II.2.2.b Protection for Pending Patents and Copyrights
II.2.2.c Exemption for Trade Secrets
II.2.2.d Exemption for Confidential Commercial Information
II.2.2.e Relationship to Circular A-110
II.2.2.f Reverse FOIA Proposal
II.2.3 National Security Exemption
II.2.4 FOIA Procedures and Logistics
II.3 Ethical Standards and Practices Protect Patient Confidentiality
II.4 Procedural Concerns Relating to Issuance of Revisions
II.5 Notice to Awardees at Time of Award
II.6 Definitions
II.6.1 Data
II.6.2 Published research findings
II.6.3 Produced under an award
II.6.4 Used
II.6.5 Developing policy or rules
II.6.6 Within a reasonable time
II.7 Cost Reimbursement
II.7.1 Introduction
II.7.2 Recommendations Regarding User Fees
II.8 Logistical Concerns Regarding Disclosure of Data
II.8.1 Data Retention
II.8.2 Attestation
II.8.3 Final Disclosure Determinations
II.8.4 Agency Enforcement
II.9 Responses to Anticipated Criticisms
II.9.1 Privacy Rights
II.9.2 Intellectual Property Rights
II.9.3 Administrative Costs and Other Burdens on Awardees
II.9.4 Definition of "Data"
II.9.5 Definition of "Published"
II.9.6 Definition of "Used"
II.9.7 Relationships with Private Funding Sources
II.9.8 Retroactivity
II.9.9 Burden on Agencies
II.10 Conclusion